Diagnostics Products (DPC) gets PSA clearance:
This article was originally published in Clinica
Diagnostics Products (US) has received US FDA clearance for its PSA radioimmunoassay. Clearance covers use as a monitor for cancer, a market estimated to be worth $200 million a year, worldwide, $100 million in the US. DPC is currently conducting clinical trials into two more prostate markers for use on its Immulite random access system in readiness for FDA submission. One is a "third generation test with exquisite sensitivity", according to president Michael Ziering.